Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review

Azali, Muhammad Azharuddin; Mohamed, Salmah; Harun, Azian; Hussain, Faezahtul Arbaeyah; Shamsuddin, Shaharum; Johan, Muhammad Farid

doi:10.1186/s43141-022-00368-7

Cited by 8 publications

(7 citation statements)

References 140 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With these advantages, the Novavax COVID‐19 vaccine derived from insect cells is currently undergoing commercialization (Azali et al . 2022). In this study, the functional CD200‐Fc recombinant protein was successfully expressed and purified in HighFive cells derived from Trichoplusia ni , which was useful as they could express between five and ten times more proteins than the S. frugiperda cell line.…”

Section: Discussionmentioning

confidence: 99%

“…Among eukaryotic expression systems with advantages such as the glycosylation of proteins and correct folding, BEVS using insect cells is easy to culture and has a low production cost, without human pathogen contaminants. With these advantages, the Novavax COVID-19 vaccine derived from insect cells is currently undergoing commercialization (Azali et al 2022). In this study, the functional CD200-Fc recombinant protein was successfully expressed and purified in HighFive cells derived from Trichoplusia ni, which was useful as they could express between five and ten times more proteins than the S. frugiperda cell line.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Insect cell‐derived human CD200‐Fc increases zonula occludens‐1 tight junction protein in urothelial carcinoma cells

Lee,

Lee

et al. 2023

Entomological Research

View full text Add to dashboard Cite

CD200 is a ligand that interacts with the CD200 receptor 1, with an anti‐inflammatory effect. CD200 inhibits the nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathway, attenuating the inflammatory response and maintaining barrier function. In this study, human CD200 was fused with the fragment crystallizable (Fc) region of human immunoglobulin G (IgG) to generate the recombinant CD200‐Fc protein, produced in insect cells using the baculovirus expression vector system. The CD200‐Fc gene was cloned under the control of the polyhedrin promoter in the pFastBac‐1 vector of the baculovirus expression vector system. Immunoblot analysis confirmed the expression of CD200‐Fc in insect cells. The CD200‐Fc protein was successfully purified using protein A affinity chromatography. 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay revealed that purified CD200‐Fc protein inhibited the proliferation of TCCSUP cells, a bladder epithelial cancer cell expressing CD200 receptor 1, at concentrations of 1, 10 and 100 ng/mL. Quantitative real‐time reverse transcription PCR (qRT‐PCR) and immunoblot analyses confirmed that the mRNA and protein levels of zonula occludens‐1, a tight junction protein for barrier protection in epithelial tissues, were increased in TCCSUP cells treated with insect cell‐derived CD200‐Fc. These results suggest that insect cell‐derived CD200‐Fc could alter zonula occludens‐1 expression in bladder epithelial cancer cells, enhancing the function of the cell barrier protein, which could inhibit cancer metastasis. Taken together, the baculovirus expression vector system can be applied to express antitumor therapeutic CD200‐Fc protein for the inhibition of bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Insect cell‐derived human CD200‐Fc increases zonula occludens‐1 tight junction protein in urothelial carcinoma cells

Lee,

Lee

et al. 2023

Entomological Research

View full text Add to dashboard Cite

show abstract

“…The development of SARS-CoV-2 vaccines is a typical example. Protein subunit and VLPs vaccines have been developed using recombinant proteins produced via BEVS [ 64 ].…”

Section: Bevs-derived Vaccinesmentioning

confidence: 99%

Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development

et al. 2023

View full text Add to dashboard Cite

Vaccination is one of the most effective strategies to control epidemics. With the deepening of people’s awareness of vaccination, there is a high demand for vaccination. Hence, a flexible, rapid, and cost-effective vaccine platform is urgently needed. The baculovirus expression vector system (BEVS) has emerged as a promising technology for vaccine production due to its high safety, rapid production, flexible product design, and scalability. In this review, we introduced the development history of BEVS and the procedures for preparing recombinant protein vaccines using the BEVS platform and summarized the features and limitations of this platform. Furthermore, we highlighted the progress of the BEVS platform-related research, especially in the field of vaccine. Finally, we provided a new prospect for BEVS in future vaccine manufacturing, which may pave the way for future BEVS-derived vaccine development.

show abstract

“…BEV produces therapeutic proteins, recombinant antibodies, MMLVRT, and ACE2 for SARS-CoV-2 diagnostic and therapy. Modified recombinant proteins increased production or stability [22].…”

Section: Pichia Pastoris -Heterologous Protein Expression In Vaccine ...mentioning

confidence: 99%

Novel Drug Development for Treatment of COVID-19 by In Silico Analysis: Identification of SARS-Cov-2 Inhibiting Streptomyces Compounds

Kumar

Gholap

Pillai

2023

Journal of Cellular Signaling

View full text Add to dashboard Cite

In accordance with the present epidemiological paradigm, viral mutations of the virus are on the rise, and their natural effects are being selected for at a higher rate than normal. According to the World Health Organization (WHO), the global COVID-19 pandemic induced by the Delta and Omicron strain of the SARS-CoV-2 virus could propagate and disseminate more rapidly than other viruses thanks to its many mutations, and these also caused some very significant health problems. The established medications would eventually start to lose their efficacy since the variation mutated more quickly than the original stain. As protein spikes are the point of origin or epitome for the mutations to take place, it would be most effective to target the remaining vital enzymes by binding the proteins with the largest pocket sizes. The objective of the current work is to employ in-silico analysis to discover the streptomyces chemicals that suppress the SARS-CoV-2 virus as well as its mutated strains thus promoting a healthy body. Based on the drug likeness property of compounds when subjected to molecular docking, a total of 14 compounds were identified and selected from the PUBCHEM database that showed highest binding energy with the targeted Receptor Binding Domain. The compounds namely - Streptomyces tanashiensis; Thaxtomin A; Bafilomycin A1 from Streptomyces griseus and few others as mentioned further on more research would support and confirm the utilizing of these to create new medications to treat the novel SARS-CoV-2 infectious strains.

show abstract

Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review

Cited by 8 publications

References 140 publications

Insect cell‐derived human CD200‐Fc increases zonula occludens‐1 tight junction protein in urothelial carcinoma cells

Insect cell‐derived human CD200‐Fc increases zonula occludens‐1 tight junction protein in urothelial carcinoma cells

Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development

Novel Drug Development for Treatment of COVID-19 by In Silico Analysis: Identification of SARS-Cov-2 Inhibiting Streptomyces Compounds

Contact Info

Product

Resources

About